Current Edition

cancer

Regeneron buys control of cancer drug Libtayo from Sanofi

Dive Brief: Regeneron will pay partner Sanofi $900 million to gain global rights to the companies’ cancer immunotherapy Libtayo, announcing Thursday a deal executives said would …

Continue Reading →
Drug

Sanofi, with positive data in hand, to ask for approval of longer-lasting hemophilia therapy

Sanofi and its development partner, the Swedish drug company Sobi, said Wednesday they plan to submit an experimental, longer-lasting hemophilia treatment for approval now that …

Continue Reading →
coronavirus

Sanofi and GSK, after delays, to seek clearance for COVID-19 vaccine

Sanofi and GlaxoSmithKline plan to seek authorization for their experimental coronavirus vaccine in the U.S. and abroad after their shot prevented COVID-19 in a large …

Continue Reading →
ABBVIE

FDA approves AbbVie, Pfizer drugs for eczema, creating competition for Sanofi

Dive Brief: The top-selling product for French pharmaceutical giant Sanofi now has two more competitors in the U.S. market, as the Food and Drug Administration …

Continue Reading →
booster

Sanofi, GSK say COVID vaccine works as booster, but delay key study results

Sanofi and GSK expected to have definitive results for their long-delayed coronavirus vaccine by now, having redesigned their shot after an initial formulation disappointed late …

Continue Reading →
data

Rebounding from setbacks, Sanofi reveals promising data for hemophilia drug

An experimental hemophilia drug cut bleeding episodes by 90% in patients who took it when compared to those given standard treatments in a late-stage clinical …

Continue Reading →
drugmakers

Sanofi claims positive early data for mRNA COVID shot, but pivots to flu instead

When drugmakers geared up to respond to the pandemic, Sanofi and GSK, as two of the largest vaccine makers, were expected to make a major …

Continue Reading →
drugs and technologies

Sanofi to buy Kadmon for $1.9B, extending deal streak

Sanofi has agreed to buy Kadmon Holdings for $1.9 billion, the latest in a string of acquisitions the French pharmaceutical giant has used to add …

Continue Reading →